Shopping Cart
- Remove All
- Your shopping cart is currently empty
Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2, IC50 = 230 pM) and acts as an antagonist of the platelet-activating factor receptor.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 89 € | In Stock | |
5 mg | 227 € | In Stock | |
10 mg | 369 € | In Stock | |
25 mg | 622 € | In Stock | |
50 mg | 885 € | In Stock | |
100 mg | 1.206 € | In Stock | |
1 mL x 10 mM (in DMSO) | 368 € | In Stock |
Description | Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2, IC50 = 230 pM) and acts as an antagonist of the platelet-activating factor receptor. |
Targets&IC50 | Lp-PLA2:230 pM |
In vitro | Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2]. |
Alias | SB 659032 |
Molecular Weight | 735.8 |
Formula | C40H38F5N3O3S |
Cas No. | 412950-08-4 |
Smiles | COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12 |
Relative Density. | 1.36g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 78 mg/mL (106 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.